Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950980 | 0.95 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4379768 | 0.90 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19547632 | 0.83 | GSR (0.41) | GSRCYP1A2MAPTTLR2 | |
| SCHEMBL15459533 | 0.81 | GSR (0.48) | GSRCYP1A2TLR2 | |
| SCHEMBL19547631 | 0.81 | GSR (0.48) | GSRCYP1A2TLR2 | |
| SCHEMBL15154020 | 0.81 | FFAR4 (0.40) | ALDH1A1MAPTAKR1B1FFAR4FFAR1 | |
| Hydrochloric Acid SCHEMBL7001555 | 0.79 | BHMT (0.42) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL10575817 | 0.79 | CA12 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10575811 | 0.79 | CA12 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1300542 | 0.79 | NOD1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761495-B1 | PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1765785-B1 | PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7435746-B2 | 5-thiopiperdinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7326698-B2 | Prostaglandin analogs | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1765785-A1 | PROSTAGLANDIN ANALOGS | Allergan, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1761495-A2 | PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS | Allergan Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20070054893-A1 | Prostaglandin analogs | ALLERGAN, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060281713-A1 | 5-Thiopiperdinyl prostaglandin e analogs | OLD DAVID W | 2006-12-14 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006014206-A1 | PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1608619-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005121086-A2 | PIPERIDINYL PROSTAGLANDIN ANALOGS AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2004094382-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | GABRP 797/4885GABRD 708/4885GABRA1 231/4885 |
| US-20060281713-A1 | 5-Thiopiperdinyl prostaglandin e analogs | PTGES, PTGES2, ALOX5 | GABRP 791/4885GABRD 1711/4885GABRA1 2574/4885 |
| US-20070054893-A1 | Prostaglandin analogs | PTGIS, PTGES, PTGIR | GABRP 1266/4885GABRD 2348/4885GABRA1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.